Members of the fibroblast growth factor receptor tyrosine kinase family (FGFR1-4) play an important role in many signalling cascades. Although tightly regulated, aberrant activity of these enzymes may lead to, or become features of, disease pathologies including cancer. FGFR isoforms have been the subject of drug discovery programmes, with a number of kinase-domain inhibitors in pre-clinical and clinical development. Here, we present the first (83% complete) backbone resonance assignments of apo-FGFR1 kinase.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s12104-013-9458-6 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!